1引言在大多数工业化国家,卒中是继心血管病和癌症之后的第三大常见死亡原因,预计其发病率会随着老年人口数量的增多而增高。尽管以减少其危险因素,如高血压、高胆固醇血症和糖尿病为目标的预防性治疗的益处已得到证实,但迄今为止,除在出现神经系统症状3h内给予溶栓药重组组织型纤溶酶原激活物(recombinant tissue plasminogen activator,rtPA)被证实有效外,尚无有效的治疗方法。 1 Introduction Stroke is the third most common cause of death after cardiovascular disease and cancer in most industrialized countries and the incidence is expected to increase with an increasing number of elderly people. Although the benefits of prophylactic treatment aimed at reducing its risk factors such as hypertension, hypercholesterolemia and diabetes have been demonstrated, to date, thrombolytic agents have been administered intramuscularly within 3 h of neurological symptoms Enzyme activator (recombinant tissue plasminogen activator, rtPA) proved effective, there is no effective treatment.